gators injected mice with endotoxin, a lipopolysaccharide derived from bacterial cell walls, and documented profound loss of contractile function in the diaphragm. This weakness was not associated with diaphragm atrophy. Neither muscle weight nor protein content was changed. Rather, weakness was wholly attributable to a decrement in force per cross-sectional area, which fell by one-half, and was linked to a rise in caspase 3 activity. Pharmacologic caspase blockade completely abolished the muscle weakness caused by endotoxin, establishing a causal relationship.
These observations are the first to demonstrate that caspase activity contributes to the weakness caused by infection. Two previous reports have associated caspase activity with myocyte apoptosis (12, 13) , suggesting a role in muscle atrophy, but caspase-induced contractile dysfunction has never been proposed in skeletal muscle. This discovery triggers a flurry of subsequent questions. For example, what causes caspase activation in muscle? What is the molecular target of caspase action that causes contractile dysfunction? Do caspases mediate weakness in other conditions that diminish force per cross-sectional area, e.g., sarcopenia of aging (3), prolonged bed rest (10), cardiac cachexia (5), and cytokine stimulation (8)?
Supinski and Callahan (9) have also identified a novel target for drug development. There is no pharmacologic intervention for the diaphragm weakness that develops during sepsis, no drug to treat the ventilatory failure that commonly occurs in these individuals. If caspase inhibitors protect diaphragm function in septic humans, such drugs would be of enormous clinical benefit in the management of critically ill patients. Clearly, the current report by Supinski and Callahan will be of interest to researchers and clinicians alike. Fig. 1 . Model of infection-induced muscle weakness. Infection increases circulating levels of inflammatory mediators, e.g., endotoxin, cytokines, and chemokines. These act on muscle cells to stimulate production of reactive oxygen species (ROS), nitric oxide (NO) derivatives, proteases, and other autocrine mediators that influence force production via two parallel mechanisms: 1) changes in myofilament function or calcium regulation can cause contractile dysfunction, decreasing force/cross-sectional area and 2) upregulation of calpains and regulatory proteins in the ubiquitin-proteasome pathway promote protein degradation, decreasing muscle mass. These 2 mechanisms have additive effects on muscle force; increases in either will promote weakness.
